COMPANY

DermaXon LLC

HQ: Missoula, MT source · dermaxon.com ↗ · Mountain

DermaXon’s goal is to develop one of our identified selective inhibitors of the different CYP26 isoforms, to increase RA concentration in the brain, and to treat memory impairment associated with AD. The company core technology is based on the design and development of small molecules modulating multiple targets or inhibiting the degradation of endogenous molecules exhibiting polypharmacology. From company website Source · Oct 13, 2026

Keywords: inhibitors small molecules exhibiting polypharmacology

Location: Missoula, MT · source · Oct 15, 2026

Profile checked Oct 10, 2026

10NIH grants

NIH awards 10

Annual award amounts. Total $3.3M.

Apr 29, 2024 NIH award 1R41DC021394-01 FY2024: $290,920 awarded for that fiscal year; activity R41 (STTR); PI DIAZ, PHILIPPE J; recipient as written: DERMAXON, LLC, MISSOULA, MT. Targeting retinoid acid metabolic pathways to trea source ↗
Sep 20, 2023 NIH award 1R43AR083781-01 FY2023: $295,423 awarded for that fiscal year; activity R43 (SBIR); PI DIAZ, PHILIPPE J; recipient as written: DERMAXON, LLC, MISSOULA, MT. Selective CYP26 inhibitors for the oral treatment source ↗
Mar 25, 2021 NIH award 1R41TR003929-01A1 FY2021: $298,132 awarded for that fiscal year; activity R41 (STTR); PI ASTRUC DIAZ, FANNY; recipient as written: DERMAXON, LLC, MISSOULA, MT. Novel therapeutic target to combat cutaneous l source ↗
Aug 29, 2019 NIH award 1R43AR076842-01 FY2019: $224,999 awarded for that fiscal year; activity R43 (SBIR); PI ASTRUC DIAZ, FANNY; recipient as written: DERMAXON, LLC, MISSOULA, MT. Topical selective T-type blockers for the treatm source ↗
Jul 18, 2019 NIH award 5R44AR069416-03 FY2019: $937,253 awarded for that fiscal year; activity R44 (SBIR); PI ASTRUC DIAZ, FANNY; recipient as written: DERMAXON, LLC, MISSOULA, MT. Selective inhibition of CYP26A1 in the skin for source ↗
Feb 28, 2019 NIH award 3R44AR069416-02S1 FY2019: $26,586 awarded for that fiscal year; activity R44 (SBIR); PI ASTRUC DIAZ, FANNY; recipient as written: DERMAXON, LLC, MISSOULA, MT. Selective inhibition of CYP26A1 in the skin for source ↗
Sep 24, 2018 NIH award 2R44AR069416-02 FY2018: $536,029 awarded for that fiscal year; activity R44 (SBIR); PI ASTRUC DIAZ, FANNY; recipient as written: DERMAXON, LLC, MISSOULA, MT. Selective inhibition of CYP26A1 in the skin for source ↗
May 4, 2018 NIH award 1R41NS105304-01A1 FY2018: $228,479 awarded for that fiscal year; activity R41 (STTR); PI ASTRUC DIAZ, FANNY; recipient as written: DERMAXON, LLC, MISSOULA, MT. Topical selective T-type blockers for the trea source ↗
Aug 25, 2016 NIH award 1R41AR069416-01A1 FY2016: $215,640 awarded for that fiscal year; activity R41 (STTR); PI ASTRUC DIAZ, FANNY; recipient as written: DERMAXON, LLC, MISSOULA, MT. Selective inhibition of CYP26A1 in the skin fo source ↗
Sep 20, 2013 NIH award 1R41AG046987-01 FY2013: $225,000 awarded for that fiscal year; activity R41 (STTR); PI ASTRUC DIAZ, FANNY; recipient as written: DERMAXON, LLC, MISSOULA, MT. Inhibition of retinoic acid metabolism for rever source ↗